Metastatic

Triple Negative ER-,PR-, HER2-

1st-3rd Line
VAR0166
Phase Ib/II Avelumab In Combination with Talazoparib in Locally Advanced or Metastatic Solid Tumors
Cohort B1 Unselected
PI: Telli
Sponsor: Pfizer

2nd - 3rd Line
BRS0050
Phase II BMN 673 in BRCA1 + BRCA2 Wild-Type Patients w/ Advanced Triple-Neg / HER2-Neg Breast Cancer
PI: Telli
Stanford

Skin mets required (Cutaneous or Subcutaneous)
BRS0090
Phase II Tavokinogene Telseplasmid + Electroporation +/- Pembrolizumab Tx in Metastatic Breast Cancer
PI: Telli
Sponsor: Onco Sec Medical Inc.

KEY
Pending
Open for Enrollment
Observational Study
Optional Path
Trial Posting
Extension Study
Immunotherapy
Enrollment on Hold